MyMD battling brain-related disorders – let’s gooooo

Sponsored By Recently we’ve been following the story of MyMD, particularly in regard to its lead drug indication – MYMD-1® – in Phase 2 trials for sarcopenia (aka aging).  But what led MyMD to pursue this path? As all companies have limited resources, Dr. Brager (Senior Executive Director of Regulatory Affairs for MyMD) overviews[here]( how companies weigh the decision to take up a new drug indication. But the main question is, “Will the new drug be able to significantly challenge the current ‘gold standard’ treatment?”   In our “user-friendly’[report](, we overviewed not 1 but 3 reasons how MYMD-1® has the potential to outperform the three Big Dog TNF-alpha inhibitors in this field. Reason #1 was covered in a recent email (MYMD-1’s ability to be taken orally)...so here is Reason #2: MYMD-1® is being positioned to treat brain-related disorders! 🧠🧠🧠MYMD-1®  is engineered in small molecule form.  In small molecule form, it can cross the blood-brain barrier and gain access to the central nervous system.   “I am not a biologist,” you say? That’s okay – as Dr. Kaplin (MyMD’s Chief Scientific Officer) explains[here](, essentially the blood brain barrier prevents substances that are harmful from entering the brain.  However, it also keeps out beneficial medications that can treat brain-related disorders, including multiple sclerosis (MS) as well as depression in age or inflammatory-related diseases.    So this ability to cross the blood-brain barrier opens up all kinds of possibilities in treating brain-related disorders.  And can the gold standards do this – NO!  None of the leaders  as identified in our[report]( can cross the blood-brain barrier because they are in[larger molecule form](.   And if this doesn’t excite you, we’ll be sharing reason #3 with you in our next email – but if you can’t wait, check out our[report]( here.  If the science doesn’t get you excited, then the price chart should! MYMD has defended a serious support level around $3.30 for over 2 weeks now. Look at the key levels right now: If we see MYMD close above $3.60, that could signal a bullish breakout and possibly a rally to the next resistance level. If you are not watching MYMD right now... you better be!  62 Calef Hwy #233 Lee, New Hampshire 03861 United States Questions or concerns about our products? Email [Support@360.com]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions  *THIS IS AN ISSUER-PAID ADVERTISEMENT, SEE DISCLOSURE BELOW*ISSUER-PAID ADVERTISEMENT. MyMD, Inc. (“MYMD” or the “Company”) HAS PAID ORWILL PAY SHERWOOD VENTURES, LLC (“Sherwood”) TWENTY-THOUSAND DOLLARS USD PER MONTH FOR THREE MONTHS (THE “INITIAL TERM”) IN CASH, SHARES OF RESTRICTED COMMON STOCK WITH A VALUE OF ONE-HUNDRED-FIFTY THOUSAND DOLLARS, AND WARRANTS VALUED AT ISSUANCE OF SEVENTY-FIVE THOUSAND DOLLARS FOR MARKETING SERVICES INCLUDING COMMUNICATING TO THE PUBLIC ABOUT THE COMPANY THROUGH SHERWOOD’S AFFILIATE RAGINGBULL.COM, LLC (“RAGING BULL”), AMONG OTHERS. THIS ADVERTISEMENT IS PART OF THOSE ISSUER-PAID MARKETING SERVICES. FOR DETAILED COMPENSATION AND MORE INFORMATION, PLEASE SEE THE FULL DISCLOSURE LOCATED AT HTTPS://BOARDROOMINVESTING.COM/MYMD-DISCLAIMER. DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of [RagingBull.com](, LLC are paid in whole or in part by commission based on their sales of Services to subscribers. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [Manage your email subscriptions.](